NCT02933528

Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use Treatment With DSXS

An Open-Label, Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use Treatment With DSXS in Patients With Moderate to Severe Scalp Psoriasis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: Sun Pharmaceutical Industries, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

An Open Label, Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use Treatment with DSXS .

Detailed description

Evaluate the potential of DSXS topical product to suppress HPA axis function in patients with moderate to severe scalp psoriasis. Evaluate the efficacy parameters and adverse event (AE) profiles of DSXS topical product administered to patients with moderate to severe scalp psoriasis.

Conditions

• Psoriasis

Interventions

Type	Name	Description
DRUG	DSXS Topical product	once daily for 28 days

Timeline

• Start date: 2016-07-11
• Primary completion: 2017-08-11
• Completion: 2017-11-27
• First posted: 2016-10-14
• Last updated: 2018-12-06
• Results posted: 2018-12-06

Locations

1 site across 1 country: United States